Loading
Prostate Cancer Treatment and Research · Journal article
Revista Fisio&terapia. · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single uncontrolled case report of a 67-year-old man with castration-resistant prostate cancer and bone metastases treated with radium-223 dichloride. The report documents laboratory changes (declining erythrocytes, elevated creatinine, reduced alkaline phosphatase) but does not report pain response, skeletal-related events, survival, or any comparative efficacy data. The findings are descriptive and do not provide evidence of clinical benefit.
Single-patient case report. One 67-year-old male with castration-resistant prostate cancer and symptomatic bone metastases at a nuclear medicine facility in Porto Velho, Brazil.. Intervention: Radium-223 dichloride (Xofigo®). n = 1. Porto Velho, Brazil.
Patient age 67 years with CRPC and symptomatic bone metastases Progressive decline in erythrocyte parameters during treatment (November 2025 to May 2026) Gradual elevation of serum creatinine during monitoring period
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case does not provide sufficient evidence to guide clinical practice. While laboratory monitoring is illustrated, no pain response, skeletal outcome, or survival data are reported; clinicians should refer to controlled trial evidence (e.g., ALSYMPCA) to inform radium-223 use in CRPC with bone metastases.
A single uncontrolled case report with laboratory monitoring but no efficacy endpoint, comparator, or outcome data; raises clinical questions but does not answer them.
As stated by the source record.
Quoted from the source exactly as published.
This case does not provide sufficient evidence to guide clinical practice. While laboratory monitoring is illustrated, no pain response, skeletal outcome, or survival data are reported; clinicians should refer to controlled trial evidence (e.g., ALSYMPCA) to inform radium-223 use in CRPC with bone metastases.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Castration-resistant prostate cancer (CRPC) with bone metastases remains a significant clinical challenge, frequently presenting with severe pain, skeletal-related events (SREs), and compromised quality of life. Radium-223 dichloride (Xofigo®) represents an innovative alpha-emitting radiopharmaceutical targeting osseous metastases. This case report describes the clinical evolution of a 67-year-old male patient with CRPC and symptomatic bone metastases treated with Radium-223 at a nuclear medicine facility in Porto Velho, Brazil. The patient demonstrated progressively declining erythrocyte parameters, gradual elevation of serum creatinine, and significant reduction in alkaline phosphatase levels during treatment monitoring from November 2025 to May 2026. These findings were consistent with expected hematologic and metabolic responses to alpha-emitter therapy. The case illustrates the importance of continuous laboratory monitoring and the potential therapeutic benefit of Radium-223 in individualized pain management for CRPC patients with metastatic bone disease. Further investigation into the long-term efficacy and safety profile of this radiopharmaceutical in Brazilian nuclear medicine practice is warranted.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.